NSUN2 and neoplasm: Overexpression of NSUN2 leads to gefitinib resistance and tumor recurrence, while genetic inhibition of NSUN2 causes tumor regression and overcomes the intrinsic resistance to gefitinib both in vitro and in vivo [174].